Coagulation Factor Xa

The third edition of the Handbook of Proteolytic Enzymes aims to be a comprehensive reference work for the enzymes that cleave proteins and peptides, and contains over 800 chapters. Each chapter is organized into sections describing the name and history, activity and specificity, structural chemistry, preparation, biological aspects, and distinguishing features for a specific peptidase. The subject of Chapter 642 is Coagulation Factor Xa. Keywords Coagulation factor, prothrombin, thrombin, proconvertin, Stuart’s factor, Prower’s factor.

• Publication year

  2012

• Venue

  Handbook of Proteolytic Enzymes

• Publication date

  2012-11-09

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/B978-0-12-382219-2.00642-6PMCID 7149769
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• A Cluster of Basic Amino Acids in the Factor X Serine Protease Mediates Surface Attachment of Adenovirus/FX Complexes

  2011cited by this paper
• Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor.

  2011cited by this paper
• Factor Xa subsite mapping by proteome-derived peptide libraries improved using WebPICS, a resource for proteomic identification of cleavage sites

  2011cited by this paper
• Biarylmethoxy isonipecotanilides as potent and selective inhibitors of blood coagulation factor Xa.

  2011cited by this paper
• Recent estimates of the structure of the factor VIIa (FVIIa)/tissue factor (TF) and factor Xa (FXa) ternary complex.

  2010cited by this paper
• Basis for the Specificity and Activation of the Serpin Protein Z-dependent Proteinase Inhibitor (ZPI) as an Inhibitor of Membrane-associated Factor Xa*

  2010cited by this paper
• Enhanced fibrinolysis by proteolysed coagulation factor Xa.

  2010cited by this paper
• Coagulation Factor Xa inhibits cancer cell migration via LIMK1-mediated cofilin inactivation.

  2010cited by this paper
• Factor X Deficiency

  2009cited by this paper
• Coagulation factor Xa inhibits cancer cell migration via protease-activated receptor-1 activation.

  2009cited by this paper
• Characterization of a homozygous Gly11Val mutation in the Gla domain of coagulation factor X.

  2009cited by this paper
• Anticoagulant activity of a sulfated galactan: Serpin-independent effect and specific interaction with factor Xa

  2009cited by this paper
• The Conformational Switch from the Factor X Zymogen to Protease State Mediates Exosite Expression and Prothrombinase Assembly*

  2008cited by this paper
• Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro.

  2008cited by this paper
• Factor Xa Active Site Substrate Specificity with Substrate Phage Display and Computational Molecular Modeling*

  2008cited by this paper
• Factor XDebrecen: Gly204Arg mutation in factor X causes the synthesis of a non-secretable protein and severe factor X deficiency

  2008cited by this paper
• Diagnosis and treatment of inherited factor X deficiency

  2008cited by this paper
• Cofactor-induced and mutational activity enhancement of coagulation factor VIIa

  2008cited by this paper
• Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity

  2007cited by this paper
• Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors.

  2007cited by this paper
• Role of the alpha-helix 163-170 in factor Xa catalytic activity.

  2007cited by this paper
• Characterization of a Factor Xa Binding Site on Factor Va near the Arg-506 Activated Protein C Cleavage Site*

  2007cited by this paper
• Role of the α-Helix 163-170 in Factor Xa Catalytic Activity*

  2007cited by this paper
• Coagulation factor Xa modulates airway remodeling in a murine model of asthma.

  2007cited by this paper
• Intermolecular interactions and characterization of the novel factor Xa exosite involved in macromolecular recognition and inhibition: crystal structure of human Gla-domainless factor Xa complexed with the anticoagulant protein NAPc2 from the hematophagous nematode Ancylostoma caninum.

  2007cited by this paper
• Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.

  2007cited by this paper
• Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet‐Induced Thrombin Generation and Prothrombinase Activity 1

  2007cited by this paper
• Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation.

  2006cited by this paper
• Prophylaxis in rare coagulation disorders -- factor X deficiency.

  2006cited by this paper
• Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.

  2005cited by this paper
• Identification of Factor Xa Residues Critical for Interaction with Protein Z-dependent Protease Inhibitor

  2005cited by this paper
• Ratcheting of the substrate from the zymogen to proteinase conformations directs the sequential cleavage of prothrombin by prothrombinase.

  2005cited by this paper
• Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease

  2004cited by this paper
• Binding of Substrate in Two Conformations to Human Prothrombinase Drives Consecutive Cleavage at Two Sites in Prothrombin*

  2004cited by this paper
• Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.

  2004cited by this paper
• Kinetics of factor Xa inhibition by recombinant tick anticoagulant peptide: both active site and exosite interactions are required for a slow- and tight-binding inhibition mechanism.

  2004cited by this paper
• Mechanisms of Factor Xa-catalyzed Cleavage of the Factor VIIIa A1 Subunit Resulting in Cofactor Inactivation*

  2003cited by this paper
• Determination of the P1', P2' and P3' subsite-specificity of factor Xa.

  2003cited by this paper
• Analysis of the Kinetics of Prothrombin Activation and Evidence That Two Equilibrating Forms of Prothrombinase Are Involved in the Process*

  2003cited by this paper
• The extended interactions and Gla domain of blood coagulation factor Xa.

  2003cited by this paper
• Preparation of vitamin K-dependent proteins, such as clotting factors II, VII, IX and X and clotting inhibitor protein C.

  2003cited by this paper
• New insight into how tissue factor allosterically regulates factor VIIa.

  2002cited by this paper
• Role of procoagulant lipids in human prothrombin activation. 2. Soluble phosphatidylserine upregulates and directs factor X(a) to appropriate peptide bonds in prothrombin.

  2002cited by this paper
• FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834.

  2001cited by this paper
• Binding of plasminogen and tissue plasminogen activator to plasmin-modulated factor X and factor Xa.

  2001cited by this paper
• Perspectives on factor Xa inhibition.

  2001cited by this paper
• Thermodynamic Linkage between the S1 Site, the Na+Site, and the Ca2+ Site in the Protease Domain of Human Coagulation Factor Xa

  2000cited by this paper
• Enhanced gamma-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide.

  2000cited by this paper
• Vitamin K-dependent proteins.

  2000cited by this paper
• Identification and Purification of Vitamin K-dependent Proteins and Peptides with Monoclonal Antibodies Specific for γ-Carboxyglutamyl (Gla) Residues*

  2000cited by this paper
• Cellular Consequences upon Factor VIIa Binding to Tissue Factor

  2000cited by this paper
• Factor Xa Activates Endothelial Cells by a Receptor Cascade Between EPR-1 and PAR-2

  2000influential reference
• Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease.

  2000cited by this paper
• Blood-borne tissue factor: another view of thrombosis.

  1999cited by this paper
• Post-translational Modifications Required for Coagulation Factor Secretion and Function

  1998cited by this paper
• Structure/function analyses of recombinant variants of human factor Xa: factor Xa incorporation into prothrombinase on the thrombin-activated platelet surface is not mimicked by synthetic phospholipid vesicles.

  1998cited by this paper
• Structural basis for chemical inhibition of human blood coagulation factor Xa.

  1998cited by this paper
• Level of Expression of Phospholipid Scramblase Regulates Induced Movement of Phosphatidylserine to the Cell Surface*

  1998cited by this paper
• Mice lacking factor VII develop normally but suffer fatal perinatal bleeding

  1997cited by this paper
• Expression, purification, and characterization of recombinant human factor X.

  1997cited by this paper
• Comparative Analysis of Haemostatic Proteinases: Structural Aspects of Thrombin, Factor Xa, Factor IXa and Protein C

  1997cited by this paper
• The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor

  1996cited by this paper
• Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation.

  1996cited by this paper
• The relative orientation of Gla and EGF domains in coagulation factor X is altered by Ca2+ binding to the first EGF domain. A combined NMR-small angle X-ray scattering study.

  1996cited by this paper
• Activation of Mac-1 (CD11b/CD18)-bound factor X by released cathepsin G defines an alternative pathway of leucocyte initiation of coagulation.

  1996cited by this paper
• The current status of coagulation.

  1995cited by this paper
• The Tissue Factor Pathway: How It Has Become a “Prima Ballerina”

  1995cited by this paper
• Structure of the Ca2+-free GLA domain sheds light on membrane binding of blood coagulation proteins

  1995cited by this paper
• Tissue Factor: molecular recognition and cofactor function

  1995cited by this paper
• Regulation of the tissue factor gene

  1995cited by this paper
• Inherited Factor VII Deficiency: Genetics and Molecular Pathology

  1995cited by this paper
• Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa.

  1994cited by this paper
• How an epidermal growth factor (EGF)-like domain binds calcium. High resolution NMR structure of the calcium form of the NH2-terminal EGF-like domain in coagulation factor X.

  1994cited by this paper
• Structure of human des(1-45) factor Xa at 2.2 A resolution.

  1993cited by this paper
• High Level Expression of Recombinant Human Tissue Factor in Chinese Hamster Ovary Cells as a Human Thromboplastin

  1991cited by this paper
• Surface-dependent reactions of the vitamin K-dependent enzyme complexes.

  1990influential reference
• Hydroxylation of aspartic acid in domains homologous to the epidermal growth factor precursor is catalyzed by a 2-oxoglutarate-dependent dioxygenase.

  1989cited by this paper
• Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis.

  1989cited by this paper
• Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque.

  1989cited by this paper
• Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells.

  1988cited by this paper
• The molecular basis of blood coagulation.

  1988cited by this paper
• Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade.

  1988cited by this paper
• Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism.

  1987cited by this paper
• The molecular basis of blood diseases

  1987cited by this paper
• Gene for human factor X: a blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C.

  1986cited by this paper
• A simple purification of human factor X using a high affinity monoclonal antibody immunoadsorbant.

  1985cited by this paper
• Purification of human brain tissue factor.

  1985cited by this paper
• Beta-hydroxyaspartic acid in vitamin K-dependent proteins.

  1983cited by this paper
• Complete amino acid sequence of the light chain of human blood coagulation factor X: evidence for identification of residue 63 as beta-hydroxyaspartic acid.

  1983cited by this paper
• Prothrombin Fragment 1.2.3, A Major Product Of Prothrombin Activation In Human Plasma

  1981cited by this paper
• Purification and properties of human coagulation factor VII.

  1980cited by this paper
• A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S.

  1977cited by this paper
• Bovine factor X 1 (Stuart factor). Mechanism of activation by protein from Russell's viper venom.

  1972cited by this paper
• Studies on bovine factor X. I. Large-sclae purification of the bovine plasma protein possessing factor X activity.

  1968cited by this paper
• Stuart clotting defect. I. Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called stable factor (SPCA, proconvertin, factor VII) deficiency.

  1957cited by this paper

• Severe Congenital Factor X Deficiency as a First Case Report in Cambodia

  2025cites this paper
• Direct Oral Anticoagulants: An Update on Monitoring and Antidotes for the Perioperative Physician

  2024cites this paper
• A roadmap to the enzymes from spider venom: biochemical ecology, molecular diversity, and value for the bioeconomy

  2024cites this paper
• Host Cell Proteases Involved in Human Respiratory Viral Infections and Their Inhibitors: A Review

  2024cites this paper
• The correlation of gene mutation of coagulopathy cascade with elevated D-dimer levels in COVID-19 patients

  2023cites this paper
• Activated protein C in epilepsy pathophysiology

  2023influential citation
• Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage

  2022cites this paper
• Identification of new pyrazolyl piperidine molecules as factor Xa inhibitors: Design, synthesis, in silico, and biological evaluation

  2022cites this paper
• Analysis of 180 Genetic Variants in a New Interactive FX Variant Database Reveals Novel Insights into FX Deficiency

  2021cites this paper
• Synthesis of 2,7-diarylpyrazolo [1,5-a] pyrimidine derivatives with antitumor activity. Theoretical identification of targets

  2021cites this paper
• Catch a tiger snake by its tail: Differential toxicity, co-factor dependence and antivenom efficacy in a procoagulant clade of Australian venomous snakes.

  2017cites this paper